| Literature DB >> 35741850 |
Paula Rovira1,2,3,4, Blanca Gutiérrez1,2,3, Antonio Sorlózano-Puerto3,5, José Gutiérrez-Fernández3,5, Esther Molina1,3,6, Margarita Rivera1,3,7, Rafael Martínez-Leal8, Inmaculada Ibanez-Casas9, María Victoria Martín-Laguna1, Araceli Rosa10, Francisco Torres-González2, Jorge A Cervilla1,2,3.
Abstract
Schizophrenia is a heterogeneous and severe psychotic disorder. Epidemiological findings have suggested that the exposure to infectious agents such as Toxoplasma gondii (T. gondii) is associated with an increased risk for schizophrenia. On the other hand, there is evidence involving the catechol-O-methyltransferase (COMT) Val105/158Met polymorphism in the aetiology of schizophrenia since it alters the dopamine metabolism. A case-control study of 141 patients and 142 controls was conducted to analyse the polymorphism, the prevalence of anti-T. gondii IgG, and their interaction on the risk for schizophrenia. IgG were detected by ELISA, and genotyping was performed with TaqMan Real-Time PCR. Although no association was found between any COMT genotype and schizophrenia, we found a significant association between T. gondii seropositivity and the disorder (χ2 = 11.71; p-value < 0.001). Furthermore, the risk for schizophrenia conferred by T. gondii was modified by the COMT genotype, with those who had been exposed to the infection showing a different risk compared to that of nonexposed ones depending on the COMT genotype (χ2 for the interaction = 7.28, p-value = 0.007). This study provides evidence that the COMT genotype modifies the risk for schizophrenia conferred by T. gondii infection, with it being higher in those individuals with the Met/Met phenotype, intermediate in heterozygous, and lower in those with the Val/Val phenotype.Entities:
Keywords: COMT; Toxoplasma gondii; case–control study; gene–environment interaction; infectious agents; schizophrenia
Mesh:
Substances:
Year: 2022 PMID: 35741850 PMCID: PMC9222771 DOI: 10.3390/genes13061088
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.141
Demographic characteristics of patients with schizophrenia and controls.
| Characteristics | Patients | Controls | |
|---|---|---|---|
| Mean age (n = 283) | 33.29 (SD = 8.58) | 39.08 (SD = 10.83) | t = 4.94, |
| Sex (n = 283) | |||
| Male | 95 (67.4) | 67 (47.2) | χ2 = 12.76, df = 1, |
| Female | 46 (32.6) | 75 (52.8) | |
| Education (n = 271) | |||
| Elementary education | 21 (16.3) | 15 (10.6) | χ2 = 7.33, df = 3, |
| Junior school | 59 (45.7) | 60 (42.3) | |
| High school | 44 (34.1) | 50 (35.2) | |
| University degree | 5 (3.9) | 17 (12) | |
| Marital status (n = 270) | |||
| Single/never married | 97 (75.2) | 41 (29.1) | χ2 = 61.03, df = 3, |
| Living with a partner | 21 (16.3) | 84 (59.6) | |
| Divorced/separated | 11 (8.5) | 15 (10.6) | |
| Widowed | 0 (0) | 1 (0.7) |
COMT allelic and genotypic frequencies in patients with schizophrenia and controls.
| Allelic and Genotypic | Controls | Patients |
|---|---|---|
| Allelic frequencies | ||
| G | 167 (58.80) | 155 (54.96) |
| A | 117 (41.20) | 127 (45.04) |
| χ2 = 0.85; df = 1; | ||
| Genotypic frequencies | ||
| G/G | 46 (32.4) | 40 (28.4) |
| G/A | 75 (52.8) | 75 (53.2) |
| A/A | 21 (14.8) | 26 (18.4) |
| χ2 = 0.95; df = 2; | ||
Frequency of T. gondii infection in patients and controls.
| Infection by | Controls (N (%)) | Patients (N (%)) |
|---|---|---|
| Yes | 29 (20.42) | 55 (39) |
| No | 113 (79.58) | 86 (61) |
| OR = 2.50; 95% CI: 1.47–4.23; | ||
Stratified analysis of levels of exposure for both COMT genotypes and T. gondii infection among cases and controls.
| Infection by | Group | Val/Val | Val/Met | Met/Met |
|---|---|---|---|---|
| No | Controls | 35 (31%) | 59 (52.2%) | 19 (16.8%) |
| Cases | 30 (34.9%) | 46 (53.5%) | 10 (11.6%) | |
| Yes | Controls | 11 (37.9%) | 16 (55.2%) | 2 (6.9%) |
| Cases | 10 (18.2%) | 29 (52.7%) | 16 (29.1%) |
Figure 1Risk for schizophrenia conferred by T. gondii infection across different COMT Val105/158Met phenotypes.
Figure 2Plausible interaction cascade between COMT and T. gondii infection in schizophrenia.